<DOC>
	<DOCNO>NCT02218047</DOCNO>
	<brief_summary>Polycythemia Vera ( PV ) disease bone marrow stem cell manifest drastic increase red blood cell frequently also white blood cell . The `` thickening '' blood relation modify function cell several consequence like increase blood pressure , pruritus skin , fatigue , disturb blood circulation brain well finger toe increase risk arterial venous thrombosis ( thrombosis formation blood clot vessel ) ; like stroke , cardiac infarction , deep vein thrombosis leg . In case strong increase platelet additional risk bleeding . As disease progress size spleen liver increase case bone marrow show sign fibrosis . In case PV progression later time point leukemia ( increased formation white blood cell ) occur . The aim study show study drug AOP2014 ( pegylated proline interferon alpha-2b ) long term efficacy safety control disease . A comparison arm receiving best available therapy select investigator . Response treatment measure several blood parameter well size spleen . Interferon-alpha show effective control blood parameter immunologically influence blood building cell . This lead suppression disease-causing stem cell help healthy stem cell proliferate . Through mechanism possible Interferon-alpha avoid long-term damaging effect disease .</brief_summary>
	<brief_title>AOP2014 v . BAT Patients With Polycythemia Vera Who Previously Participated PROUD-PV Study .</brief_title>
	<detailed_description>This Phase III , parallel-arm , open-label continuation PROUD-PV study perform adult diagnose Polycythemia Vera ( PV ) . Patients receive AOP2014 primary study , PROUD-PV continue AOP2014 , patient receive HU PROUD-PV study receive best available therapy select investigator . Only patient complete PROUD-PV include end study visit enrol continuation study .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients complete 12 month AOP2014 treatment arm PROUDPV study `` endoftreatment visit '' ( EoT ) PROUDPV study fulfill least one follow criterion : normalization least two three main blood parameter ( Hct , PLTs WBCs ) parameter moderately increase ( Hct &lt; 50 % , WBC &lt; 20 x 109/L , PLTs &lt; 600 x 109/L ) baseline PROUDPV study , OR &gt; 35 % decrease least two three main blood parameter ( Hct , PLTs WBCs ) parameter massively increase ( Hct &gt; 50 % , WBCs &gt; 20 x 109/L , PLTs &gt; 600 x 109/L ) , baseline PROUDPV study , OR normalization spleen size , spleen enlarge baseline PROUDPV study , OR otherwise clear , medically verified benefit treatment AOP2014 ( e.g . normalization diseaserelated microvasculatory symptom , substantial decrease JAK2 allelic burden ) . 2 . Signed write ICF . Exclusion criterion : Withdrawal criterion , specify PROUDPV study , mandate treatment discontinuation : 1 . Nonrecovery AOP2014 related toxicity grade ( usually , Grade I ) allow continuation treatment . 2 . HADS score 11 high either subscales , /or development worsen clinically significant depression suicidal thought . 3 . Progressive clinically significant increase liver enzyme level despite dose reduction , increase accompany increased bilirubin level , sign symptom clinically significant autoimmune disease . 4 . Clinically significant development new ophthalmologic disorder , worsen preexist one , study . 5 . Loss efficacy AOP2014 comparable situation benefit treatment continuation expect investigator . The main efficacy evaluation criterion disease response define Hct &lt; 45 % without phlebotomy ( least 3 month since last phlebotomy ) , PLTs &lt; 400 x 109/L , WBCs &lt; 10 x 109/L , normal spleen size . The main efficacy endpoint maintenance rate disease response assessment visit ( every three month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pegylated-Proline-interferon alpha-2b ( AOP2014 )</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>PROUD-PV</keyword>
	<keyword>CONTINUATION-PV</keyword>
	<keyword>AOP Orphan</keyword>
	<keyword>Polycythemia</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Peginterferon alfa-2b</keyword>
</DOC>